BioSpace News Archive

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes.

Applied Genetic Technologies Corporation and a newly established portfolio company of Syncona Limited, announced the commencement of the previously announced tender offer for all of the issued and outstanding shares of common stock of AGTC at a price of $0.34 per share in cash, at the closing of the transaction, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.

Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share.

CANbridge Pharmaceuticals Inc. announced that the company’s partner Mirum Pharmaceuticals, Inc. reported positive topline data from its Phase 3 MARCH study evaluating the safety and efficacy of LIVMARLI® oral solution in patients with progressive familial intrahepatic cholestasis.

Antengene Corporation Limited announced that it will host its R&D Day for the investment community on November 15th and November 17th since its inception to review Antengene’s R&D strategy and pipeline, the commercial launch of XPOVIO® underway in China and other markets in Asia, and other important company updates.

Complete Genomics, part of MGI, celebrates the US commercial launch of their DNBSEQTM sequencing product line at the American Society of Human Genetics Annual Meeting, from October 25-29, in Los Angeles.

Verona Pharma plc announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Bristol Myers Squibb announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis.

ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently.

Oncopeptides AB announces data from the phase 3 LIGHTHOUSE study that further confirms the clinical benefit of melflufen in patients with relapsed refractory multiple myeloma.